Biotechnology
Sitryx To Participate In Upcoming Healthcare Investor Conferences
Share
Oxford, UK and Boston, MA – November 13, 2025 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announced that management will be participating in three upcoming healthcare conferences:
Jefferies Global Healthcare Conference 2025
Date: November 17-20, 2025
Location: London, UK
Format: 1x1 Meetings
Piper Sandler 37th Annual Healthcare Conference 2025
Date: December 2-4, 2025
Location: New York, USA
Format: Presentation and 1x1 Meetings
Presentation date and time: December 2, 11:50-12:10pm ET
RBC Healthcare Private Company Conference 2025
Date: December 11, 2025
Format: Virtual Fireside Chat and 1x1 Meetings
Management will be in attendance to participate in one-on-one and group meetings during each event. Interested investors should contact their Jefferies, Piper Sandler and RBC representatives, respectively, to schedule meetings.
Ends
For more information about Sitryx please contact:
ICR Healthcare
Mary-Jane Elliott, David Daley, Evi Useh
+44 (0)20 3709 5700
Sitryx@icrhealthcare.com
About Sitryx
Sitryx is a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease. The Company has a broad pipeline of novel small molecule candidates targeting major autoimmune indications with high unmet need. Its lead candidate, SYX-5219, is a potentially first-in-class PKM2 modulator in development for atopic dermatitis as a once-daily oral therapy with future development potential across multiple autoimmune diseases.
Established in 2018 with seed funding from SV Health Investors, Sitryx has an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Oxford Science Enterprises, Longwood Fund, Eli Lilly and Company, and GSK.
Sitryx is headquartered in Oxford, UK with additional presence in Boston, MA. For more information, please visit www.sitryx.com.
Frequently Asked Questions
What does Sitryx Therapeutics do?
Sitryx Therapeutics is a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory diseases.
What is Sitryx's lead candidate?
Sitryx's lead candidate is SYX-5219, a potentially first-in-class PKM2 modulator in development for atopic dermatitis as a once-daily oral therapy.
Where is Sitryx headquartered?
Sitryx is headquartered in Oxford, UK, with an additional presence in Boston, MA.
First published on Thu, Nov 13, 2025
Enjoyed what you've read so far? Great news - there's more to explore!
Stay up to date with the latest news, a vast collection of tech articles including introductory guides, product reviews, trends and more, thought-provoking interviews, hottest AI blogs and entertaining tech memes.
Plus, get access to branded insights such as informative white papers, intriguing case studies, in-depth reports, enlightening videos and exciting events and webinars from industry-leading global brands.
Dive into TechDogs' treasure trove today and Know Your World of technology!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.
Trending GlobeNewswire
HERE Technologies And Amazon To Showcase Next-Generation AI Navigation For Automakers At CES 2026
Kelyn Technologys Data Protection And Resilience Solutions Added To Carahsofts National Association Of State Procurement Officials (NASPO) Valuepoint Contract
Leading Semiconductor Company Taps Articul8 To Accelerate Product Release Cycles With Domain-Specific Genai
Menlo Ventures Announces Promotion Of Deborah Carrillo To Partner
Socialboom.Io Launches Service To Assist Users In Buying Instagram Likes And Followers
Join Our Newsletter
Get weekly news, engaging articles, and career tips-all free!
By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.
Join The Discussion